Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact.
Adolescent
Adult
Aged
Antimalarials
/ therapeutic use
Artemisinins
/ therapeutic use
Child
Child, Preschool
Diagnostic Tests, Routine
/ statistics & numerical data
Feasibility Studies
Female
Fever
/ diagnosis
Humans
Infant
Malaria, Falciparum
/ diagnosis
Male
Mass Screening
/ statistics & numerical data
Middle Aged
Plasmodium falciparum
/ isolation & purification
Quinolines
/ therapeutic use
Senegal
Young Adult
Malaria elimination
Plasmodium falciparum
Population-wide interventions
Testing and treatment
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
14 Jul 2020
14 Jul 2020
Historique:
received:
26
06
2019
accepted:
04
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
3
3
2021
Statut:
epublish
Résumé
Population-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed. A pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA. During MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person. It was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Population-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed.
METHODS
METHODS
A pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA.
RESULTS
RESULTS
During MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person.
CONCLUSIONS
CONCLUSIONS
It was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.
Identifiants
pubmed: 32664939
doi: 10.1186/s12936-020-03313-6
pii: 10.1186/s12936-020-03313-6
pmc: PMC7362450
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
252Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1148921
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Am J Trop Med Hyg. 1994 Aug;51(2):123-37
pubmed: 8074247
Malar J. 2016 Aug 11;15(1):408
pubmed: 27515533
Parasit Vectors. 2012 Apr 04;5:69
pubmed: 22475528
Lancet. 2010 Nov 6;376(9752):1566-78
pubmed: 21035842
J Clin Microbiol. 2011 Nov;49(11):3885-91
pubmed: 21880972
PLoS One. 2011;6(5):e20179
pubmed: 21629651
Am J Trop Med Hyg. 2015 May;92(5):913-921
pubmed: 25802434
Clin Infect Dis. 2017 May 1;64(9):1221-1227
pubmed: 28369268
Malar J. 2011 Nov 03;10:337
pubmed: 22050911
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents
pubmed: 19136431
Nat Commun. 2012;3:1237
pubmed: 23212366
Malar J. 2013 Feb 27;12:79
pubmed: 23442748
J Infect Dis. 2015 May 1;211(9):1476-83
pubmed: 25429102
Trop Med Int Health. 2015 Nov;20(11):1438-1446
pubmed: 26171642
Lancet. 2016 Apr 23;387(10029):1775-84
pubmed: 27116283
Malar J. 2011 Apr 13;10:86
pubmed: 21489278
PLoS One. 2012;7(2):e31743
pubmed: 22363717